- Home
- PFE vs AMGN Comparison
PFE vs AMGN Comparison
Compare PFE & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFE
- AMGN
- Stock Information
- Founded
- PFE 1849
- AMGN 1980
- Country
- PFE United States
- AMGN United States
- Employees
- PFE N/A
- AMGN N/A
- Industry
- PFE Biotechnology: Pharmaceutical Preparations
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFE Health Care
- AMGN Health Care
- Exchange
- PFE Nasdaq
- AMGN Nasdaq
- Market Cap
- PFE 134.2B
- AMGN 155.9B
- IPO Year
- PFE N/A
- AMGN N/A
- Fundamental
- Price
- PFE $23.97
- AMGN $290.36
- Analyst Decision
- PFE Hold
- AMGN Buy
- Analyst Count
- PFE 14
- AMGN 21
- Target Price
- PFE $29.92
- AMGN $323.62
- AVG Volume (30 Days)
- PFE 38.6M
- AMGN 2.8M
- Earning Date
- PFE 07-29-2025
- AMGN 08-05-2025
- Dividend Yield
- PFE 7.18%
- AMGN 3.29%
- EPS Growth
- PFE N/A
- AMGN 56.16
- EPS
- PFE 1.38
- AMGN 10.94
- Revenue
- PFE $62,464,000,000.00
- AMGN $34,126,000,000.00
- Revenue This Year
- PFE N/A
- AMGN $7.73
- Revenue Next Year
- PFE N/A
- AMGN $1.69
- P/E Ratio
- PFE $17.36
- AMGN $26.44
- Revenue Growth
- PFE 11.65
- AMGN 15.56
- 52 Week Low
- PFE $20.92
- AMGN $253.30
- 52 Week High
- PFE $31.54
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- PFE 53.24
- AMGN 54.94
- Support Level
- PFE $23.08
- AMGN $286.60
- Resistance Level
- PFE $24.95
- AMGN $299.49
- Average True Range (ATR)
- PFE 0.39
- AMGN 5.47
- MACD
- PFE 0.02
- AMGN 0.21
- Stochastic Oscillator
- PFE 48.15
- AMGN 46.50
About PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.